Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P19086

UPID:
GNAZ_HUMAN

ALTERNATIVE NAMES:
G(x) alpha chain; Gz-alpha

ALTERNATIVE UPACC:
P19086; B2R6C1; Q4QRJ6

BACKGROUND:
Guanine nucleotide-binding protein G(z) subunit alpha, known alternatively as G(x) alpha chain or Gz-alpha, is integral to the modulation and transduction of signals across cell membranes. This protein's function in G protein-coupled receptor (GPCR) signaling pathways highlights its importance in cellular communication and response mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Guanine nucleotide-binding protein G(z) subunit alpha presents a promising avenue for the development of novel therapeutic interventions. Its key role in signal transduction pathways offers a valuable target for designing drugs that can precisely modulate its activity, potentially leading to breakthrough treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.